for people ages 18 years and up (full criteria)
at UC Davis UCSD
study started
estimated completion



This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Official Title

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)


Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Gemcitabine, Bevacizumab, Cisplatin, Carboplatin, Docetaxel, Pemetrexed, Atezolizumab, Vemurafenib, Entrectinib, Alectinib, Cobimetinib, GDC-6036, Alectinib 600 Milligrams (mg), Atezolizumab 1200 mg, Entrectinib 600 Milligrams (mg), Atezolizumab, Vemurafenib, and Cobimetinib, Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed


You can join if…

Open to people ages 18 years and up

  • Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • Measurable disease
  • Adequate recovery from most recent systemic or local treatment for cancer
  • Adequate organ function
  • Life expectancy greater than or equal to (>/=) 12 weeks
  • For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception

You CAN'T join if...

  • Inability to swallow oral medication
  • Women who are pregnant or lactating
  • Symptomatic, untreated CNS metastases
  • History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
  • Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina
  • Known human immunodeficiency virus (HIV) positivity or autoimmune deficiency syndrome (AIDS)-related illness
  • Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
  • Inability to comply with other requirements of the protocol


  • University of California San Diego withdrawn
    La Jolla California 92093 United States
  • UC Davis; Comprehensive Cancer Center accepting new patients
    Sacramento California 95817 United States


accepting new patients
Start Date
Completion Date
Hoffmann-La Roche
Phase 2/3 research study
Study Type
Expecting 1000 study participants
Last Updated